Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Status:
Recruiting

Trial end date:
2024-06-19

Target enrollment:

Participant gender:

The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.

Phase 2

Amgen